Ulrich Blaschke, PhDVice President, Technical Development at BioNTech AG
Ulrich Blaschke joined BioNTech in December 2019 as VP of Technical Development. In this role, he is responsible for the implementation of an integrated CMC development strategy for the BioNTech portfolio, working closely with the technical functions and CMC regulatory affairs. Besides the technical aspects, he is specifically interested in the evolving global regulatory framework for this new class of therapeutic molecules.
Prior to BioNTech, Ulrich worked for various pharmaceutical companies in Germany and in the US, including CureVac, Boehringer Ingelheim, Cinfa Biotech, and Stada Arzneimittel.
Ulrich studied chemistry and biochemistry at the Westfälische-Wilhelms University in Münster, Germany, followed by a postdoctoral fellowship in the field of synthetic protein chemistry at the Rockefeller University, New York.